Incidence and antimicrobial profile of extended-spectrum β-lactamase producing gram-negative bacterial isolates: An in-vitro and statistical analysis

• Main Authors: Turki M.S. Dawoud (Author), Asad Syed (Author), Amit Kumar Maurya (Author), Syed Sayeed Ahmad (Author), Quazzafi Rabbani (Author), Abdullah A. Alyousef (Author), Abdulaziz Alqasim (Author), Mohammed Arshad (Author), Mohd Sajid Khan (Author), Mohammad Khalid (Author), Haroon Khan (Author), Maria Daglia (Author)
• Format: Book
• Published: Elsevier, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objectives: There is an extensive incidence of extended-spectrum beta-lactamases (ESBLs), principally in the hospital environment across the world. The present study was designed to discover the frequency of ESBL-production among the clinical isolates of Escherichia coli, Klebsiella pneumonia, and Pseudomonas aeruginosa. The study also focused on determining their liability to the selected antimicrobials. Methods: Two hundred ten (210) clinical specimens were tested for the occurrence of ESBL using the double-disc synergy test. The molecular, physicochemical, absorption, distribution, metabolism, excretion, and toxicity were checked through an online server. Results: Among the screened clinical isolates, E. coli (n = 44), K. pneumonia (n = 34) and P. aeruginosa (n = 14) were ESBL markers. The ESBL producing isolates exhibited co-resistance to diverse categories of antibiotics. It was observed that all the ESBL-producing isolates were sensitive towards imipenem and faropenem with minimal proportion of resistance. Conclusion: The imipenem and faropenem can be recommended as the drugs of selection due to a lesser amount of resistance as compared to other antibiotics in this study.

Item Description

1876-0341
10.1016/j.jiph.2020.06.026